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Opioid growth factor modulates
angiogenesis
John Blebea, MD,a James E. Mazo, MD,a Todd K. Kihara, MD,a Jonathan-
Hien Vu, MD,a Patricia J. McLaughlin, DEd,b Robert G. Atnip, MD,a and
Ian S. Zagon, PhD,b Hershey, Pa
Objective: Induced angiogenesis has recently been attempted as a therapeutic modality in
patients with occlusive arterial atherosclerotic disease. We investigated the possible role
of endogenous opioids in the modulation of angiogenesis.
Methods: Chick chorioallantoic membrane was used as an in vivo model to study angio-
genesis. Fertilized chick eggs were incubated for 3 days, explanted, and incubated for an
additional 2 days. Three-millimeter methylcellulose disks were placed on the surface of
the chorioallantoic membrane; each disk contained opioid growth factor ([Met5]-
enkephalin; 5 µg), the short-acting opioid receptor antagonist naloxone (5 µg), opioid
growth factor and naloxone together (5 µg of each), the long-acting opioid antagonist
naltrexone (5 µg), or distilled water (control). A second series of experiments was per-
formed with distilled water, the angiogenic inhibitor retinoic acid (1 µg), and vascular
endothelial growth factor (1 µg) to further evaluate our model. The developing vascu-
lature was imaged 2 days later with a digital camera and exported to a computer for
image analysis. Total number of blood vessels, total vessel length, and mean vessel length
were measured within a 100-mm2 region surrounding each applied disk.
Immunocytochemical analysis was performed with antibodies directed against opioid
growth factor and its receptor (OGFr).
Results: Opioid growth factor had a significant inhibitory effect on angiogenesis, both
the number of blood vessels and the total vessel length being decreased (by 35% and
20%, respectively) in comparison with control levels (P < .005). The simultaneous addi-
tion of naloxone and opioid growth factor had no effect on blood vessel growth, nor did
naloxone alone. Chorioallantoic membranes exposed to naltrexone displayed increases of
51% and 24% in blood vessel number and length, respectively, in comparison with con-
trol specimens (P < .005). These results indicate that the opioid growth factor effects are
receptor mediated and tonically active. Immunocytochemistry demonstrated the pres-
ence of both opioid growth factor and OGFr within the endothelial cells and mes-
enchymal cells of the developing chorioallantoic membrane vessel wall. Retinoic acid sig-
nificantly reduced the number and the total length of blood vessels, whereas vascular
endothelial growth factor increased both the number and the length of blood vessels in
comparison with the controls (P < .0001). The magnitude of opioid growth factor’s
effects were comparable to those seen with retinoic acid, whereas inhibition of opioid
growth factor with naltrexone induced an increase in total vessel length comparable to
that for vascular endothelial growth factor.
Conclusions: These results demonstrate for the first time that endogenous opioids mod-
ulate in vivo angiogenesis. Opioid growth factor is a tonically active peptide that has a
receptor-mediated action in regulating angiogenesis in developing endothelial and mes-
enchymal vascular cells. (J Vasc Surg 2000;32:364-73.)
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Atherosclerosis affects more than 20 million
people in the United States.1 Approximately 1 mil-
lion patients undergo either coronary artery bypass
grafting or balloon angioplasty/stenting each year,
and more than 100,000 patients have lower extrem-
ity arterial revascularization.2 In addition, more than
100,000 patients require leg amputations each year
because of infection or advanced atherosclerotic dis-
ease not amenable to present revascularization
modalities. Recent studies have suggested that
exogenous angiogenic growth factors can stimulate
the peripheral development of collateral arteries in
patients with critical limb ischemia, thus inducing
therapeutic angiogenesis and avoiding amputations
in selected patients.3-5 Conversely, inhibition of
angiogenesis has been studied in patients with life-
threatening hemangiomas, ocular neovasculariza-
tion, and cancer.6,7
The pentapeptide [Met5]-enkephalin is an
endogenous opioid directly involved in growth
processes and serves as a negative regulator in a wide
variety of cells and tissues.8,9 In view of the function
and distribution of [Met5]-enkephalin, this peptide
has been termed opioid growth factor (OGF). The
effects of OGF are dose related, noncytotoxic,
receptor mediated, and effective at concentrations
consistent with the binding affinity of its receptor.
Importantly, OGF also has been shown to be an
autocrine-produced peptide that inhibits DNA syn-
thesis in endothelial cells, smooth muscle cells, and
fibroblasts in the rat aorta.10,11
Given the influence of endogenous opioids, par-
ticularly OGF, on DNA synthesis in the rat aorta, we
hypothesized that blood vessel development is
dependent on the regulatory capabilities of opioid
peptides. In the current study, we examined this 
thesis in the chorioallantoic membrane (CAM)
model.12 To address the question of whether angio-
genesis is dependent on OGF, we exposed CAMs to
methylcellulose disks impregnated with the peptide
and measured total numbers of blood vessels and
vessel length. CAMs were subjected to disks con-
taining OGF and naloxone, the short-acting and
low-potency opioid antagonist, to explore whether
OGF’s effects are receptor mediated. Finally, CAMs
were treated with the long-acting and potent opioid
antagonist naltrexone to determine whether OGF is
a constitutively expressed growth factor. Preliminary
immunocytochemical experiments were performed
to document the presence of OGF and its receptor,
OGFr, on the vessels in the developing CAM. The
validity of the CAM model with respect to the effect
of OGF on angiogenesis was investigated through
use of the known inhibitor of angiogenesis, retinoic
acid, and the known stimulant of angiogenesis, vas-
cular endothelial growth factor (VEGF).
MATERIALS AND METHODS
Chorioallantoic model. The CAM model used
in these studies has been described previously.12 In
brief, fertilized white broiler chicken eggs were
obtained from a local hatchery and kept at room
temperature for 48 hours. The outsides of the shells
were washed with soap, and the eggs were placed in
a 70% ethyl alcohol bath for 30 seconds. The eggs
were then incubated at 37°C for 3 days and rotated
180 degrees three times daily. After incubation, the
eggs were cleansed with an iodine solution and dried
on a sterile tray. They were then cracked, and the
embryos were explanted into spherical plastic 100 ×
25-mm weigh boats. Specimens were covered with a
plastic lid, placed in a humidified chamber at 37°C,
and maintained for 48 to 72 hours until the CAM
achieved at least a 10-mm diameter.
Drug delivery. Methylcellulose disks were pre-
pared as reported previously.12 Five micrograms of
each of the following were prepared in 10 µL of dis-
tilled water and combined in equal parts with a
methylcellulose solution: OGF (n = 10), OGF and
naloxone simultaneously (n = 9), naloxone alone (n
= 11), and naltrexone (n = 10). These doses were
selected on the basis of prior animal and culture
studies.10,13 An equivalent volume of distilled water
was used as a control (n = 13). In another series of
experiments, retinoic acid (1 µg)14 (n = 12), VEGF
(1 µg)15 (n = 10), and an equivalent volume of water
(n = 10) were used to validate the CAM model and
provide an internal comparison of the potential
angiogenic effects of OGF with those of other
known angioactive agents. These methylcellulose
solutions were placed on the tips of 3.2-mm diame-
ter Teflon (DuPont, Wilmington, Del) rods and
allowed to dry at room temperature for 1 hour
under a vacuum hood. The resultant dried disks
were removed from the Teflon rods and placed on
the outer third of the CAMs. Only one disk was
placed on each CAM. The eggs were returned to the
incubator for an additional 48 hours of growth
before examination by image analysis.12
Immunocytochemistry. Two 8-day-old CAMs
were prepared for immunocytochemistry to examine
for the presence of OGF and its receptor (OGFr).
Each CAM, along with its vessels, was dissected
from the embryo, placed on a glass slide, and frozen
by immersion in isopentane cooled by dry ice. The
frozen tissue was sectioned (10 µm) and collected
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on gelatin-coated slides. Sections were fixed in 95%
ethanol and acetone, rinsed in Sorenson’s phosphate
buffer (SPB), and blocked with SPB and 3% normal
goat serum for 15 minutes. Immunocytochemistry
was performed according to previously published
procedures.16,17 In brief, polyclonal immunoglobu-
lin G antibodies to OGF (anti-[Met5]-enkephalin,
CO-172) and OGFr (AO-440) were diluted 1:100
in SPB with 1% normal goat serum and 0.1% Triton
X-100 (Boehringer Mannheim, Indianapolis, Ind).
Tissues were incubated with the primary antibodies
in a humidified chamber at 4°C for 20 hours,
washed, and then incubated with rhodamine-conju-
gated goat antirabbit immunoglobulin G (1:100;
Cappel Laboratories, Malvern, Pa) for 45 minutes.
Control tissues were sections of CAM stained with
antibodies preabsorbed for 24 hours with an excess
of the appropriate antigen ([Met5]-enkephalin or
the receptor-binding protein). Matching frozen sec-
tions were stained with hematoxylin and eosin for
structure identification.
Image analysis. Image analysis was performed as
described previously.12 The disk was located visually
on the CAM. An identifying mark was placed in the
center of the disk, and 2 mL of a 10% intralipid solu-
tion was injected into the CAM, obscuring the under-
lying yolk vessels and providing an opaque white
background for the superficial vessels. The CAM was
imaged on a three-chip digital camera (DKC 500,
Sony, Tokyo, Japan), digitized, and exported to a per-
sonal computer (Fig 1). A 100-mm2 region was
defined around the disk in which blood vessel quanti-
tation was performed (Optimas 6.0, Mediacybernetics,
Bothell, Wash). Calibration was achieved by imaging a
ruler placed adjacent to the embryo preparation.
All arteries and veins in this designated region cen-
tered on the applied disk were analyzed. From the dig-
itized image, an overlying mask was created and all
blood vessels were traced within the region in an
unblinded manner by two different investigators. The
blood vessels were counted, and their individual
lengths were added to obtain total blood vessel length.
Fig 1. Digitized computer images of 7-day-old CAMs. In contrast to control specimens (A),
CAMs treated with retinoic acid (B) exhibited marked decrease in blood vessel growth in 100-
mm2 region around disk. After treatment with OGF (C), blood vessel growth is suppressed in
comparison with control samples. Vessel inhibition is no longer seen after treatment with nal-
trexone (D). Note circle representing applied disk (cross-hatched arrow) and surrounding
blood vessels (arrow). Bar = 5 mm.
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For the immunocytochemical specimens, micro-
scopic images were obtained with an Olympus BH-2
microscope (Tokyo, Japan) equipped for fluorescence
microscopy and digitized, as described. Fluorescence
intensities, areas, and numbers of particles were deter-
mined through software imaging analysis (Scion
Image Rel 3b, Scion Corp, Frederick, Md).
Statistics. Data were exported to Microsoft
Excel (Excel 97, Microsoft, Redmond, Wash). Each
value was expressed as a mean ± SEM. Statistical
analysis was performed through use of the SigmaStat
1.0 statistical software package (Jandel, San Rafael,
Calif). The Mann-Whitney rank sum test or the
Student t test was used to compare continuous data.
Either the Fischer exact test or the χ2 test was used
for dichotomous data. A P value of less than .05
indicated statistical significance.
RESULTS
Neither OGF nor its inhibitors appeared to be
toxic, inasmuch as all embryos survived the addi-
tional 48 hours after placement of drug onto the
CAM. In comparison with the controls, application
of disks impregnated with the endogenous opioid
peptide OGF had a marked inhibitory effect on
angiogenesis (Fig 1, C). OGF significantly decreased
the number of blood vessels by 35% in comparison
with the controls (Table and Fig 2). Moreover, the
OGF group demonstrated a 20% decrease in total
blood vessel length in comparison with the controls
(Table and Fig 3). Mean blood vessel length in the
OGF group, however, increased significantly from
control values (23%) because of a disproportionate
decrease in total number of blood vessels (35%;
Table and Fig 4).
Naloxone, a short-acting opioid antagonist, was
added simultaneously with OGF to the CAM to
investigate whether the inhibitory effects of OGF on
angiogenesis were mediated at the level of the opioid
receptor. The concomitant administration of OGF
and naloxone completely neutralized the inhibitory
effect of OGF on angiogenesis, as reflected by the
Effects of angiogenic factors on blood vessel growth
Blood vessels
Total Mean
length length 
Treatment Number (mm) (mm)
Control (n = 13) 157 ± 14 224 ± 12 1.47 ± 0.06
OGF (n = 10) 102 ± 11* 179 ± 12* 1.81 ± 0.13†
Retinoic acid 79 ± 10‡ 153 ± 11‡ 2.07 ± 0.13‡
(n = 12)
VEGF (n = 10) 358 ± 16‡ 280 ± 7‡ 0.79 ± 0.02‡
Each value is given as mean ± SEM.
*Significantly different from controls; P < .005.
†Significantly different from controls; P < .001.
‡Significantly different from controls; P < .0001.
Fig 2. Comparison of total numbers of blood vessels in
region around applied disks. Number of blood vessels is
significantly decreased in OGF group and increased in nal-
trexone group in comparison with control preparations.
Significant differences from controls: *P < .005; #P <
.001.
Fig 3. Total blood vessel length is significantly inhibited
in CAMs exposed to OGF and increased after treatment
with naltrexone. Simultaneous treatment with naloxone
prevented inhibition by OGF. Significant difference from
controls: *P < .005.
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number of blood vessels (Fig 2), total blood vessel
length (Fig 3), and mean blood vessel length (Fig 4).
Naxolone alone had no effect on vessel growth in
comparison with control values. The number and
length of blood vessels in the CAMs treated with
naloxone were significantly greater than those in the
OGF-treated group (Figs 2-4; P < .0001).
The CAM was subjected to the long-acting opioid
receptor antagonist naltrexone to determine whether
angiogenesis reflected the constitutive expression of
opioid peptides (Fig 1, D). Preparations subjected to
naltrexone had a 51% increase in number of blood ves-
sels (Fig 2) and a 24% increase in total blood vessel
length (Fig 3) relative to control specimens. Mean
blood vessel length in the naltrexone group exhibited
a marked decrease in comparison with what was seen
in the control group.
Immunocytochemical analysis documented the
presence of both OGF and its receptor in the
endothelial cells lining the lumen of the developing
vessels and throughout the surrounding mesenchymal
cells of the vessel wall (Fig 5). The peptide and its
receptor were localized to the cytoplasm of the cells
and did not appear to be in the cell nuclei. The cumu-
lative area of immunofluorescence was 4475 µm2 for
the OGF peptide and 8280 µm2 for the OGFr in a
0.011-mm2 region of interest centered on the vessel
lumen; this compared with no detectable fluorescence
(0.0 µm2) for each of the respective controls.
Retinoic acid, a known inhibitor of angiogene-
sis,14,18,19 displayed an inhibitory effect on blood
vessel growth at the dosage used (Fig 1, B and Figs
6-8). Retinoic acid–treated CAMs had a 60%
decrease in number of blood vessels (Fig 6) and a
33% decrease in total blood vessel length (Fig 7) in
comparison with the control group (Figs 6 and 7).
Mean blood vessel length of the retinoic acid–treated
group, however, increased by 75% relative to that of
the control group (Fig 8). No significant differences
were found between the OGF-treated and retinoic
acid-treated groups with regard to number of blood
vessels, total vessel length, or mean vessel length.
VEGF, a known stimulant of angiogenesis,15 dis-
played an excitatory effect on blood vessel growth
(Figs 6-8). In comparison with what was seen in the
control specimens, VEGF increased total vessel
length by 22% (Fig 6) and the number of blood ves-
sels by 83% (Fig 7), and there was an associated
decrease in mean blood vessel length of 33% (Fig 8).
Total vessel length was not different from that seen
in the naltrexone-treated group, but with VEGF the
total number of blood vessels was greater (P < .0001)
and the mean vessel length was shorter (P < .0001).
DISCUSSION
Our results demonstrate for the first time that an
endogenous opioid peptide, OGF, is an inhibitory
substance associated in vivo with angiogenesis. Both
number of visible blood vessels and total vessel length
were found to be dependent on OGF activity. These
effects of a native opioid peptide on blood vessel
growth appear to be cytostatic rather than cytotoxic,
because systemic embryo growth and survival were
not affected.12
Local or regional cytotoxicity cannot explain the
inhibition of angiogenesis by OGF. The combination
of OGF and naloxone, a short-acting opioid receptor
antagonist without intrinsic biologic activity,20 neutral-
ized OGF activity. If cytotoxicity were the explanation
of vessel inhibition, the presence of naloxone would
not have reversed angiogenic inhibition. Cell and tis-
sue culture studies also do not support such a hypoth-
esis. For example, studies with tissue culture cells have
shown the reversibility of cell growth inhibition when
application of exogenous OGF is eliminated.13 In
studies of the rat neonatal aorta in which thymidine
labeling was used to quantify DNA synthesis, coincu-
bation with both OGF and naloxone prevented the
decrease in DNA synthesis induced by OGF in both
endothelial cells and smooth muscle cells.10 Similarly,
a time-limited effect of systemic administration of
OGF to 4 hours was demonstrated.10 All of these
results provide convincing evidence that the inhibitory
effects of OGF are not due to cytotoxicity.
Fig 4. Mean blood vessel length is significantly increased
by treatment with OGF, whereas naltrexone decreased
mean blood vessel length. Significant differences from
controls: #P < .001; †P < .0005.
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Fig 5. Immunocytochemical preparation of isolated principal CAM vessels. Cross section of vessel stained with hematoxylin-
eosin shows its morphologic structure at this early developmental stage, with flattened inner endothelial cells (arrows) and
mesenchymal presumptive immature smooth muscle cells (curved arrow) (A). Sections of vessels have been incubated with
antibodies to OGF (B, C) or OGF receptor (D, E) at 1:100 dilutions. Note staining of cytoplasm (arrowheads) of cells
throughout wall of vessels and nonstaining of nuclei. Fig 5, C and E shows control sections stained with antibodies to OGF
and OGF receptor, respectively, after preabsorption with excess OGF and OGF receptor; they did not exhibit any immuno-
fluorescence. Times of exposure and printing correspond in all photos. Bar = 48 µm for Fig 5, A and 16 µm for Fig 5, B-E.
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The effect of OGF on angiogenesis is receptor
mediated because naloxone, the opioid receptor
antagonist, blocked OGF’s suppressive activities on
blood vessel growth when OGF and naloxone were
administered concomitantly at a dose of naloxone
that had no effect alone. The current studies also
revealed that OGF is constitutively expressed and
tonically active. The potent and longer-acting opioid
antagonist naltrexone, through a persistent blockade
of opioid-receptor interaction, markedly stimulated
blood vessel development. This is hypothesized to
represent inhibition of endogenous OGF activity.
Both naloxone and naltrexone are biologically inert
molecules with no documented independent effects
on cellular growth or proliferation.20,21 Although
determination of the full extent of OGF’s modula-
tory action on angiogenesis awaits further studies,
one can surmise, at least to some degree, the magni-
tude of this peptide’s regulatory abilities. Thus,
exogenous OGF application to the CAM decreased
the number of blood vessels by 35% and blood ves-
sel length by 20% in comparison with control sub-
jects, which reveals the presumable potential influ-
ence on angiogenesis when receptor sites are satu-
rated. Moreover, blockade of endogenous OGF
activity by naltrexone resulted in a 51% increase in
number of blood vessels and a 24% increase in blood
vessel length in comparison with control specimens,
which indicates the constitutive influence of endoge-
nous opioid action. Thus, an approximate contribu-
tion of both exogenous and endogenous opioid
activity suggests that opioid peptides can regulate
the number of blood vessels by approximately 86%
of control values and can regulate blood vessel
length by 44% in comparison with controls within a
very short period (ie, 48 hours).
Fig 8. Inhibition of new vessel development by retinoic
acid increased calculated mean vessel length, whereas
VEGF is associated with decreased values in comparison
with control preparations (§P < .0001).
Fig 6. In another series of experiments, angiogenic
inhibitor retinoic acid has significantly diminished number
of blood vessels, whereas VEGF markedly increased angio-
genesis (§P < .0001).
Fig 7. Retinoic acid decreased total length of measured
blood vessels whereas VEGF induced marked increase in
comparison with controls (§P < .0001).
Although we have used OGF in the current
study to ascertain that endogenous opioids modu-
late angiogenesis, it is unknown whether this is the
most potent or the only opioid peptide involved
with blood vessel growth. Some information, how-
ever, emanates from the study of Zagon et al,10 in
which a wide variety of synthetic and natural opioids
were administered to a 1-day-old rat and the label-
ing index of the aorta was determined. Only OGF—
[Met5]-enkephalin—altered DNA synthesis. There-
fore, if parallels can be extended between developing
vasculature and the model of angiogenesis in this
study, one may tentatively conclude that OGF is the
opioid peptide selective for angiogenesis. In a relat-
ed study, Pasi et al22 reported that β-endorphin and
morphine sulfate reduced the number of blood ves-
sels in a CAM model. In contrast to what was seen
in the current study with OGF, the effects of β-
endorphin and morphine sulfate were not blocked
by concomitant exposure to naloxone. Thus, admin-
istration of opioids may result in a similar depression
in number of blood vessels, but the pathways
responsible for this action appear to be entirely dif-
ferent for OGF and β-endorphin and morphine sul-
fate.
The cellular and molecular mechanism(s) under-
lying the modulation of angiogenesis herein are
unclear. Some information, however, comes from
other reports in which OGF has been shown to reg-
ulate DNA synthesis of endothelial, smooth muscle,
and fibroblast cells in the developing rat aorta and to
do so in a dose-dependent and receptor-mediated
manner.8 Both OGF and its receptor have been
detected in the cytoplasm of all three cell types in the
neonatal aorta, and this peptide has been discovered
to be autocrine produced.8-10 As in the rat aorta,11
this study demonstrates the cytoplasmic presence of
the receptor and OGF in endothelial cells and
throughout the vessel wall in developing CAM ves-
sels (Fig 5). The definitive identification of the spe-
cific cells in the vessel wall—other than the luminal
endothelial cells—is difficult at this intermediate
stage of embryonic development, but most are
thought to be immature smooth muscle cells.23,24
Nonetheless, localization of OGF and OGFr, both
on the endothelial cells and on these mesenchymal
cells, indicates that the effects of OGF on angiogen-
esis are not limited to endothelial cells. In this man-
ner, OGF is analogous to other angiogenic growth
factors, such as basic fibroblast growth factor
(bFGF), tumor necrosis factor α, and transforming
growth factor β, which also act on smooth muscle
cells.25 The results of the current study predict that
both the peptide and its receptor are present on
angiogenic endothelial and smooth muscle cells and
that OGF interacts with its receptor directly at the
cellular level. Moreover, if the data from the devel-
oping vasculature are of relevance, OGF may regu-
late the emergence of angiogenic architecture by
controlling cell generation. The increase in mean
blood vessel length by OGF and the associated
decrease by the inhibitor naltrexone suggest that
shorter budding vessels are being modulated by the
opioid system. This is consistent with our hypothe-
sis that angiogenesis, the branching out of new ves-
sels from preexisting structures, is the process that is
being studied in this acute animal model.
A number of substances have been reported to
affect angiogenesis.25,26 To begin to compare the
magnitude of suppression of angiogenesis induced by
OGF with that for other inhibitory substances, the
effects of retinoic acid on blood vessel growth were
evaluated. At the dose of retinoic acid used, the sum-
mation of exogenous and endogenous opioid activity
depressed angiogenesis to a greater degree than did
retinoic acid. The mechanisms for OGF and retinoic
acid with respect to growth modulation appear to dif-
fer. Retinoic acid has been reported to induce differ-
entiation and apoptosis, with these effects mediated
through both cytosolic and nuclear receptors.26 OGF,
however, acts at the locus of a specific opioid receptor
and directly influences cell proliferation. VEGF, which
has a potent and specific effect on endothelial cell pro-
liferation,15 produced a marked increase in the total
number and length of blood vessels in this model. At
the dosages used, naltrexone inhibition increased the
total length of blood vessels to the same extent as did
OGF (277 ± 10 mm and 280 ± 7 mm, respectively).
The total number and the mean vessel length were dif-
ferent for the two groups. This suggests a comparable
magnitude of effect on angiogenesis by VEGF and
OGF but indicates that the pathways are different.
The clinical implications of OGF with regard to
the etiology and pathogenesis of angiogenic abnor-
malities, as well as to the treatment of such disorders,
merit consideration. In the case of excessive blood
vessel growth, such as with cancers and hem-
angiomas, OGF and/or its receptor may be in low
abundance because of transcription or translational
irregularities. In the case of a reduction in blood ves-
sel development, excessive quantities of OGF and/or
OGFr may be overly suppressive of angiogenesis and
may be associated with subsequent developmental
malformations. Thus, treatment with an opioid
antagonist or opioid agonist (ie, OGF) may be of
therapeutic benefit in such circumstances.
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More recently, both laboratory and clinical inves-
tigations have demonstrated the potential benefits of
inducing angiogenesis in adults.27 Using a rabbit
model of hindlimb ischemia, Takeshita et al28 success-
fully achieved percutaneous transarterial gene transfer
of VEGF. This endothelial cell mitogen was found to
increase the development of collateral blood vessels in
the hindlimb and to improve measured blood flow. In
a similar manner, Lazarous et al29 found the angio-
genic peptide bFGF to enhance cardiac collateral ves-
sel development in the dog.29 Most important, mole-
cular induction of angiogenesis has now reached the
stage of human experimentation. Baumgartner et al30
have reported on successful intramuscular injection
therapy with naked plasmid DNA encoding for
human VEGF in nine patients with ischemic heel
ulcers or rest pain. The patients were reported to have
experienced significant and persistent increases in
their ankle-brachial indexes, and there was healing or
marked improvement in four of the seven patients
with heel ulcers. Successful adenoviral gene transfer of
human VEGF has also been achieved in 21 patients
with direct myocardial injection.31
In contradistinction to both VEGF and bFGF,
opioid receptor blockade offers a potentially faster
and less invasive mode of therapy. Opioid antago-
nists, such as naltrexone, are approved for clinical
use and have established records of clinical safety.
Naltrexone has no opioid agonist activity, is an oral
agent, and is presently used in the treatment of alco-
holic and narcotic addiction. Its potential use, along
with that of other angiogenic agents, for nonrecon-
structible extremity ischemia may represent the
beginning of a new era in the treatment of vascular
ischemic disease.
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